GAD and Cormorbidity: Impact on Patient Health

Dr. Naomi M. Simon, Associate Director of the Center for Anxiety and Traumatic Stress Disorders
Generalized Anxiety Disorder (GAD) is common, chronic, and associated with substantial impairment in function and quality of life. GAD commonly occurs comorbid with mood disorders and anxiety disorders. GAD comorbidity has been clearly linked to additive worsening of outcomes and function in both Major Depressive Disorder and in Bipolar Disorder. This presentation will provide an update on current understandings about the incidence and nature of GAD and comorbid disorders, and their impact on patient health.

During this webinar attendees will:

1) Understand the overlap of Generalized Anxiety Disorder (GAD) with mood disorders

2) Understand the impact of GAD comorbidity on severity of illness including suicidality, quality of life and functioning in individuals with GAD

3) Learn about the need to address GAD and its comorbidities to optimally improve patient health

Naomi Michele Simon, M.D., M.Sc.

Dr. Naomi M. Simon is Associate Director of the Center for Anxiety and Traumatic Stress Disorders and Director of the recently established Complicated Grief Program at Massachusetts General Hospital, and is Associate Professor of Psychiatry, Harvard Medical School.

Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME5
Nov 9 2010
66 mins
GAD and Cormorbidity:  Impact on Patient Health
More from this community:

Medical Research

Webinars and videos

  • Live and recorded (184)
  • Upcoming (9)
  • Date
  • Rating
  • Views
  • Attend this webinar to discover:

    ·Insight from BRIC healthcare leaders as they share field experiences and best practices gathered through hundreds of successful cases
    ·Common obstacles international companies must overcome in these regions
    ·How to exploit the hidden potential of BRIC countries
    ·Tactics to adjust strategy to successfully penetrate BRIC markets
    ·The top 10 technologies and products expected to drive growth in these regions
  • Advances in the understanding of the behavior and function of biological systems are dependent on the study of cells and tissues. An essential tool in this research is the use of in vitro cell culture. Many variables contribute to providing a physiological environment for the cell in the laboratory, a few examples include cell source, isolation techniques, growth conditions such as matrix proteins and soluble factors, and cell age. Basic laboratory practices are sometimes overlooked as a source of discrepancy in data; however the application of fastidious and reproducible technique can reduce cell culture as a source of data variation. As specialized techniques have been developed to modulate cells and tissues in vitro, the importance of reproducible data has become paramount. In this presentation, we will identify and discuss basic principles of in vitro mammalian cell culture that influence the quality of experimental results.
  • Attend this webinar to discover:

    •Evaluate market potential for basic and advanced medical imaging modalities
    •Learn about important market characteristics and trends
    •Identify opportunities for growth in medical imaging equipment markets within each region of the world
    •Consider factors affecting market growth internationally
  • As the healthcare industry across APAC moves toward digitization, electronic health information exchange becomes a stepping stone to success. Governments, non-profit entities and the private sector are aggressively investing in Electronic Medical Record (EMR) and Electronic Health Record (EHR) systems. This Frost & Sullivan briefing presents a comprehensive analysis of the EMR and EHR markets in APAC, with special focus on emerging opportunities in the region.

    Why You Should Attend:
    - Learn about the rapidly developing EMR and EHR markets in APAC
    - Understand key market drivers and restraints
    - Identify leading market participants and their role in the competitive environment
    - Recognize areas of growth within this space
  • In recent decades, the nasal and bronchial mucosa has become an established administration site for systemic as well as local drug delivery. For developing novel drugs intended for this route, reliable methods are needed for assessing the rate and extent of absorption across the nasal and bronchial epithelium. Epithelix has developed a novel in vitro cell model of the human airway epithelium named MucilAir™. MucilAir™ maintains the fully differentiated, morphologically and functionally, characteristics of the native tissues for more than one year. Using this system, the typical characteristics of the airway epithelium are observed (e.g. tight junctions, cilia beating, ciliated cells, basal cells, mucous cells, cytokine/chemokine/metalloproteinase release, active ion transport and CypP450s activity). Epithelia from several pathologies can be reconstructed (e.g. Asthma, Allergic Rhinitis, COPD, CF, etc.). Due to its unique long shelf-life, this model is used for studying the human respiratory diseases, and for testing the long-term/chronic effects of drugs candidates on respiratory tract. Several applications of MucilAir™ relevant to drug delivery, inhalation efficacy and toxicity assessment will be presented. For each application, specific examples of in vitro tests will be selected to highlight the Pros and Cons of using in vitro human airway epithelia for development of new drug candidates for respiratory diseases.
  • Glucuronidation is as a major pathway for the metabolism and elimination of drugs in humans. It is second only to P450 for the metabolic clearance of currently marketed drugs. The glucuronidation reaction is catalyzed by the Phase 2 enzyme UDP-glucuronosyltransferase (UGT), which like the P450s exists as a superfamily of enzymes with broad and overlapping substrate specificities. Identification of the UGT isoforms important for the glucuronidation of new chemical entities is essential for predicting and avoiding the risk of adverse reactions due to either drug-drug interactions or genetic polymorphisms. This webinar will provide an in depth overview of in vitro methods for studying UGT pathways. Important parameters for setting up UGT assays using tissue fractions and recombinant UGT enzymes will be discussed, as well as the methods and tools currently available for conducting UGT reaction phenotyping studies.
  • What is CAPPS? … short for Complex Abdominal -Pelvic Pain Syndrome, CAPPS is a syndrome of nonmalignant origin consisting of a complex of abdominal and pelvic symptoms that includes a variety of painful bowel, bladder, genital, reproductive, muscular and nerve dysfunctions lasting at least 3-6 months in duration.

    Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) patients often have overlapping chronic conditions, including fibromyalgia, irritable bowel syndrome, vulvodynia, endometriosis, pudendal neuralgia, pain with sexual intimacy, pelvic floor dysfunction, obstructing adhesions, lichen sclerosis, and even TMJ, as well as psycho-social issues that often develop as a result of these difficult conditions.

    Attempting to treat these disorders as separate entities is often a frustrating task for patients and practitioners alike. Although these conditions may start out separately, they may be better diagnosed, assessed and treated as essentially connected disorders of pain processing in the pelvic region — CAPPS.

    In this webinar, Robert J. Echenberg, MD, FACOG, will discuss not only IC/PBS’s role in CAPPS, but also the multi-disciplinary and holistic approach that is needed in order to most effectively treat what most practitioners call “chronic pelvic pain (CPP). He will explain how IC/PBS should be considered as a “major player” in the broader context of “connecting the dots” in this family of all too common and debilitating conditions.

    This ICA webinar is made possible with the generous support of Innovation Compounding.
  • This presentation seeks to highlight:
    - Market projections for the global medical devices market
    - Identification of market sectors and sub-sectors poised for expansion
    - Discussion of key market opportunities in emerging markets
    - Strategies for success in the new market paradigm
  • This briefing will investigate how regulations and hospital needs stimulate the EMR market in Latin America and will specially focus on how these regulations will potentially encourage the EMR implementation until 2017.

    Why You Should Attend:
    ·Learn about the market dynamics of EMR in the region
    ·Identify the drivers and restraints impacting the EMR market for the next six years
    ·Discover business opportunities
  • Top Five Asia Pacific Growth Sectors:
    •Medical Tourism: Driven by rising affluence and increasing demand for quality healthcare, medical tourism is one of the top growth sectors in APAC in the short to medium term.
    •Outpatient Surgery: This is a lucrative business option that requires less investment, with more profitability.
    •Specialty Hospitals: Due to increasing lifestyle diseases, such as diabetes and coronary heart disease, Asia Pacific is a large marketplace for specialty hospitals.
    •Private Medical Insurance: The increasing cost of healthcare, coupled with low penetration rates of public insurance, creates an expansive market for private insurance companies. Consumer empowerment will also spike private medical insurance revenues.
    •Healthcare IT: To remain competitive by increasing operational efficiency, clinical outcomes and financial profitability, private and public hospitals will invest extensively in installing, maintaining and upgrading IT capabilities.
  • Channel
  • Channel profile
Up Down
  • GAD and Substance Abuse Recorded: Nov 23 2010 70 mins
    Substance use disorders commonly co-occur with anxiety disorders. Diagnosing anxiety disorders in the face of active substance use and withdrawal can be very challenging due to the significant symptom overlap. This symptom overlap often leads to delayed or inadequate treatment. When treating individuals with generalized anxiety disorder and a substance use disorder, benzodiazepines should be avoided. Selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors are FDA-approved to treat GAD and are fairly safe in substance users. Other non-FDA approved medications will also be discussed.

    During this webinar, attendees will learn:

    -What symptoms of anxiety overlap with substance use and withdrawal

    - How to diagnose anxiety disorders in the face of substance use

    -Why substance abuse and anxiety disorders co-occur so frequently

    -How to treat individuals with anxiety disorders and comorbid substance abuse

    Dr. Susan Sonne is active in research and teaching as Associate Professor of Psychiatry and Pharmacy at the Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Clinical Neuroscience Division.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme6
  • GAD and Cormorbidity: Impact on Patient Health Recorded: Nov 9 2010 66 mins
    Generalized Anxiety Disorder (GAD) is common, chronic, and associated with substantial impairment in function and quality of life. GAD commonly occurs comorbid with mood disorders and anxiety disorders. GAD comorbidity has been clearly linked to additive worsening of outcomes and function in both Major Depressive Disorder and in Bipolar Disorder. This presentation will provide an update on current understandings about the incidence and nature of GAD and comorbid disorders, and their impact on patient health.

    During this webinar attendees will:

    1) Understand the overlap of Generalized Anxiety Disorder (GAD) with mood disorders

    2) Understand the impact of GAD comorbidity on severity of illness including suicidality, quality of life and functioning in individuals with GAD

    3) Learn about the need to address GAD and its comorbidities to optimally improve patient health

    Naomi Michele Simon, M.D., M.Sc.

    Dr. Naomi M. Simon is Associate Director of the Center for Anxiety and Traumatic Stress Disorders and Director of the recently established Complicated Grief Program at Massachusetts General Hospital, and is Associate Professor of Psychiatry, Harvard Medical School.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME5
  • Treating Older Adults with Generalized Anxiety Disorder Recorded: Oct 27 2010 76 mins
    By 2050 there will be over 150 million older adults with anxiety disorders globally. Symptoms include sleep disturbance, interference with daily activities and distress, which can lead to medical illness such as coronary heart disease, disability, and higher levels of health care utilization.

    Attendees will learn:
    - How anxiety disorders in older adults differ from the disorders in younger adults.
    ~ They can be more detrimental to health and cognition in older adults.
    ~ These disorders may be more treatment-resistant, requiring aggressive treatment such as the combination of medication and psychotherapy.
    - Why late-life anxiety disorders are undetected and undertreated.
    - The benefits of using antidepressants and Cognitive-Behavioral Therapy as safer alternatives to treatment for these disorders in older adults.

    Webinar Speaker:
    Eric Lenze, MD
    Associate Professor, Department of Psychiatry, Washington University School of Medicine

    Dr. Lenze completed medical school and psychiatry residency at Washington University School of Medicine. He trained in a geriatric psychiatry fellowship and a clinical research fellowship at University of Pittsburgh, then joined the faculty, as part of the Advanced Center for Interventions and Services Research in Late-life mood disorders. In 2007, he returned to Washington University to focus on treatment studies in late-life anxiety disorders and depression. He carries out clinical research in disabled rehabilitating elderly populations and runs a faculty practice treating late-life anxiety disorders and depression.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme4
  • Treating GAD in Primary Care Settings Recorded: Oct 13 2010 78 mins
    Attendees will:
    - recognize symptoms of Generalized Anxiety Disorder in primary care patients
    - use current pharmacological and psychotherapeutic treatments to develop a management plan
    - assess different treatments for comorbid GAD and refractory cases

    Webinar Speaker:
    Larry Culpepper, MD, MPH
    Professor of Family Medicine and Chairman, Department of Family Medicine, Boston University

    Dr. Culpepper has conducted federally funded studies of depression and anxiety, otitis media, and school-based and community interventions to improve pregnancy outcomes and to prevent teen pregnancies. He currently is the principal investigator of an AHRQ funded developmental center for patient safety research devoted to the study of problems affecting low income and minority vulnerable populations in ambulatory care settings, and co-investigator of the Primary Care Anxiety Project, a study of the course of anxiety disorders in primary care settings.

    Dr. Culpepper also is Chief of Family Practice at Boston Medical Center. He received his MD degree from Baylor College of Medicine and his MPH degree from Boston University.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme3
  • Psychosocial Treatments for Generalized Anxiety Disorder Recorded: Oct 8 2010 72 mins
    Attendees will:
    - Discuss current evidence-based psychotherapeutic treatments for adults with generalized anxiety disorder.
    - Identify characteristics of generalized anxiety disorder.
    - Design a psychosocial treatment plan with patients with GAD.

    Webinar Speaker:
    Douglas Mennin, PhD
    Associate Professor of Psychology, Yale University and Director of the Yale Anxiety and Mood Services Clinic

    Dr. Mennin has focused his research program on understanding and treating chronic and reoccurring bouts of anxiety and mood disorders, particularly worry, stress, and depression. Our understanding of problems related to anxiety and depression has increased exponentially in the past twenty years. Advances in biological and behavioral technologies has helped us shine light on how everyday feelings such as fear and sadness can, in some individuals, translate into emotional disorder.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME2
  • Understanding & Treating Generalized Anxiety Disorder Recorded: Sep 21 2010 77 mins
    Attendees will:
    - discuss the neurobiology of GAD
    - recognize symptoms and diagnose individuals with generalized anxiety disorder
    - plan evidence-based treatment for individuals with GAD and gad and comorbid disorders including depression, sleep disorders, cardiac illnesses and IBS.

    Webinar speaker:
    Mark Pollack, MD, Director, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital
    Professor of Psychiatry, Harvard Medical School

    Dr. Pollack’s areas of clinical and research interest include the acute and long-term course, pathophysiology, and treatment of patients with anxiety disorders and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME1
Anxiety disorders are real, serious & treatable
Anxiety disorders are real, serious & treatable

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: GAD and Cormorbidity: Impact on Patient Health
  • Live at: Nov 9 2010 5:00 pm
  • Presented by: Dr. Naomi M. Simon, Associate Director of the Center for Anxiety and Traumatic Stress Disorders
  • From:
Your email has been sent.
or close
You must be logged in to email this